Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 5, 2004, Pages 1570-1576

  Donnelly, Erling T ^a   Liu, Yanfeng ^a   Fatunmbi, Yetunde O ^a   Lee, Intae ^b   Magda, Darren ^b   Rockwell, Sara ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PHARMACYCLICS INC   (United States)

Author keywords

Hypoxia; Motexafin gadolinium; Texaphyrins; Tumor oxygenation; Xcytrin

Indexed keywords

METALS; MUSCLE; OXYGEN; TUMORS;

MAMMARY TUMORS; NONLANTHANIDE METALS;

RADIOTHERAPY;

DYSPROSIUM; EUROPIUM; GADOLINIUM; GADOLINIUM TEXAPHYRIN; LANTHANIDE; LUTETIUM; MANGANESE; MANNITOL; PORPHYRIN DERIVATIVE; TEXAPHYRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST TUMOR; DRUG EFFECT; HYPOXIA; IMPLANT; LEG MUSCLE; MODULATION; MOUSE; NONHUMAN; OXIMETRY; OXYGEN BLOOD LEVEL; OXYGEN TENSION; OXYGENATION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANIMALS; CELL HYPOXIA; CELL RESPIRATION; DYSPROSIUM; MAMMARY NEOPLASMS, ANIMAL; MANGANESE COMPOUNDS; METALLOPORPHYRINS; MICE; MICE, INBRED BALB C; OXYGEN; PORPHYRINS;

EID: 1842424239     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.12.017     Document Type: Article

References (42)

1. Gray L.H., Conger A.D., Ebert M., et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 26:1953;638-648.
2. Thomlinson R.H., Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 9:1955;539-549.
3. Gray L.H. Radiobiologic basis of oxygen as a modifying factor in radiotherapy. Am J Roentgenol. 85:1961;803-815.
4. Moulder J.E., Rockwell S. Tumor hypoxia Its impact on cancer therapy. Cancer Metastasis Rev. 19:1987;197-202.
5. Rockwell S. Oxygen delivery Implication for the biology and therapy of solid tumors. Oncol Res. 9:1997;383-390.
6. Nordsmark M., Overgaard M., Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 41:1996;31-40.
7. Brizel D.M., Sibley G.S., Prosnitz L.R., et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 38:1997;285-290.
8. Fyles A.W., Milosevic M., Wong R., et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 48:1998;149-156.
9. Sessler J.L., Murai T., Lynch V., et al. An "expanded porphyrin:" The synthesis and structure of a new aromatic pentadentate ligand. J Am Chem Soc. 110:1988;5586-5588.
10. Sessler J.L., Mody T.D., Hemmi G.W., et al. Synthesis and structural characterization of lanthanide(III) texaphyrins. Inorg Chem. 32:1993;3175-3187.
11. Sessler J.L., Mody T.D., Hemmi G.W., et al. Gadolinium(III) texaphyrin - a novel MRI contrast agent. J Am Chem Soc. 115:1993;10368-10369.
12. Sessler J.L., Miller R.A. Texaphyrins New drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol. 59:2000;733-739.
13. Mody T.D., Fu L., Sessler J.L. Texaphyrins Synthesis and development of a novel class of therapeutic agents. Prog Inorg Chem. 49:2001;551-598.
14. Young S.W., Sidhu M.K., Qing F., et al. Preclinical evaluation of gadolinium(III) texaphyrin complex. Invest Radiol. 29:1994;330-338.
15. Young SW, Qing F, Harriman A, et al. Gadolinium(III) texaphyrin: A tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci U S A 1996;93:6610-6615 (Correction). Proc Natl Acad Sci U S A 1999;96:2569
16. Young SW, Qing F, Harriman A, et al. Gadolinium(III) texaphyrin: A tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci U S A 1996;93:6610-6615 (Correction). Proc Natl Acad Sci U S A 1999;96:2569
17. Rosenthal D.I., Nurenberg P., Becerra C.R., et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res. 5:1999;739-745.
18. Miller R.A., Woodburn K.W., Fan Q., et al. In vivo animal studies with gadolinium(III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys. 45:1999;981-989.
19. Viala J., Vanel D., Meingan P., et al. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging Preliminary results in brain metastases. Radiology. 212:1999;755-759.
20. Bernhard E.J., Mitchell J.B., Deen D., et al. Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent. Cancer Res. 60:2000;86-91.
21. Xu S., Zakian K., Thaler H., et al. Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol Biol Phys. 49:2001;1381-1390.
22. Woodburn K.W. Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric fourier fluorescence microscopy. J Pharmacol Exp Ther. 297:2001;888-894.
23. Carde P., Timmerman R., Mehta M.P., et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol. 19:2001;2074-2083.
24. Sessler J., Tvermoes N., Guldi D., et al. One-electron reduction and oxidation studies of the radiation sensitizer gadolinium (III) texaphyrin (PCI-0120) and other water soluble metallotexaphyrins. J Phys Chem A. 103:1999;787-794.
25. Magda D., Lepp C., Gerasimchuk N., et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys. 51:2001;1025-1026.
26. Rockwell S., Donnelly E.T., Liu Y., et al. Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro. Int J Radiat Oncol Biol Phys. 54:2002;536-541.
27. Mehta M.P., Shapiro W.R., Glantz M.J., et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol. 20:2002;3445-3453.
28. Woodburn K.W., Fan Q., Kessel D., et al. Phototherapy of cancer and atheromatous plaque with texaphyrins. J Clin Laser Med Surg. 14:1996;343-348.
29. Sessler J.L., Dow W.C., O'Connor D., et al. Biomedical applications of lanthanide(III) texaphyrins. Lutetium texaphyrins as potential PDT photosensitizers. J Alloys Compd. 249:1997;146-152.
30. Rockson S.G., Kramer P., Razavi M., et al. Photoangioplasty for human peripheral atherosclerosis Results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin). Circulation. 102:2000;2322-2324.
31. Griffin G.M., Zhu T., Solonenko M., et al. Preclinical evaluation of motexafin lutetium-mediated intraperitoneal photodynamic therapy in a canine model. Clin Cancer Res. 7:2001;374-381.
32. Rockwell S. In vivo-in vitro tumor systems New models for studying the response of tumors to therapy. Lab Anim Sci. 27:1977;831-851.
33. Moulder J.E., Rockwell S. Hypoxic fractions of solid tumors Experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys. 10:1984;695-712.
34. Collingridge DR, Rockwell S. Pentoxifylline improves the oxygenation and radiation response of BA112 rat rhabdomyosarcomas and EMT6 mouse mammary carcinomas. Int J Cancer (Radiat Oncol Invest) 2000;90:256-264.
35. Dunst J., Hangsen G., Lautenschlager C., et al. Oxygenation of cervical cancers during radiotherapy + cis-retinoic acid/interferon. Int J Radiat Oncol Biol Phys. 43:1999;367-373.
36. Shakil A., Osborn J.L., Song C.W. Changes in oxygenation status and blood flow in a rat tumor model by mild temperature hyperthermia. Int J Radiat Oncol Biol Phys. 43:1999;859-865.
37. Zywietz F., Reeker W., Kochs E. Change in tumor oxygenation during a combined treatment with fractionated irradiation and hyperthermia An experimental study. Int J Radiat Oncol Biol Phys. 37:1997;155-162.
38. Rockwell S., Mate T.P., Irvin C.G., et al. Reactions of tumors and normal tissues in mice to irradiation in the presence and absence of a perfluorochemical emulsion. Int J Radiat Oncol Biol Phys. 12:1986;1315-1318.
39. Rockwell S., Kelly M., Irvin C.G. Effects of the perfluorochemical emulsion FMIQ on the radiation response of EMT6 tumors. Int J Radiat Biol. 6:1992;833-839.
40. Rockwell S., Kelley M. RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy Preliminary studies with EMT6 cells and tumors and normal tissues in mice. Radiat Oncol Investig. 6:1998;199-208.
41. Vaupel P., Kelleher D.K., Höckel M. Oxygenation status of malignant tumors Pathogenesis of hypoxia and significance of tumor therapy. Semin Oncol. 28:2001;29-35.
42. Secomb T.W., Hsu R., Ong E.T., et al. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol. 34:1995;313-316.